By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
OncoMed Pharmaceuticals, Inc. (OMED) Says FDA Lifts Partial Hold On Cancer Drug Trials For Vantictumab 8/28/2014 7:41:38 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Second Quarter 2014 Financial Results 8/7/2014 9:00:29 AM
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014 7:27:10 AM
OncoMed Pharmaceuticals, Inc. (OMED) Granted Broad FZD-Fc Composition-Of-Matter And Use Patent In U.S. 7/2/2014 7:15:21 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The 9th Annual JMP Securities Healthcare Conference 6/19/2014 8:27:40 AM
OncoMed Pharmaceuticals, Inc. (OMED) Provides Update on FZD8-Fc (OMP-54F28) Phase I Clinical Trials 6/19/2014 8:25:52 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents Data For Notch1 Diagnostic Assay At The 19th European Hematology Association Congress 6/16/2014 7:42:07 AM
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Voluntarily Halts Early-Stage Trials for Two Cancer Drugs 6/13/2014 7:39:54 AM
MolecularMD Develops Notch1 Next Generation Sequencing Test To Support Clinical Development For OncoMed Pharmaceuticals, Inc. (OMED)'s Anti-Notch1 Antibody, OMP-52M51 6/12/2014 10:08:39 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present Data For Notch1 Program At The 19th European Hematology Association Congress 6/4/2014 8:57:23 AM
123456789
//-->